It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about ...

According to the lawsuit, throughout the Class Period, the Company and its senior executives misled investors and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, ...

New York, New York-- (Newsfile Corp. - March 13, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) ...

TransMedics Group (NASDAQ:TMDX – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a ...

The organ transplant technology specialist significantly exceeded Wall Street's estimates in the fourth quarter.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate ...

TransMedics' strong Q4 performance and market share growth signal a promising future for investors. Click here to find out ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

TransMedics is revolutionizing organ transplant therapy with its FDA-approved Organ Care System. See why I rate TMDX stock as a buy.

TransMedics Group's organ care system can preserve multiple organs, but livers are responsible for 70% of total sales. OrganOx markets a normothermic machine perfusion device approved to preserve ...

TransMedics Group specializes in organ transplantation technology through its Organ Care System (OCS), which replaces the long-standard static cold storage method for organ preservation with a ...

It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about 62% from the peak it set last August. The company's warm perfusion ...